| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A PHASE 1B/2, OPEN-LABEL, MASTER PROTOCOL STUDY OF BTK-DEGRADER BGB-16673 IN COMBINATION WITH OTHER AGENTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES |
I/II |
in corso |
- SC Ematologia Oncologica |
||
IDENTIFICARE LE CARATTERISTICHE CLINICO-PATOLOGICHE DELLE PAZIENTI CON DIAGNOSI DI TUMORE NEUROENDOCRINO DELL'OVAIO |
NA |
in corso |
CARCINOMA NEUROENDOCRINO OVAIO |
- SC Oncologia Clinica Sperimentale dei Sarcomi e Tumori Rari |
|
A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF 225AC-PSMA-TRILLIUM IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) |
I |
in corso |
CARCINOMA PROSTATICO |
- SC Medicina Nucleare e Terapia Metabolica |
|
A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED TRIAL OF TRASTUZUMAB DERUXTECAN WITH BEVACIZUMAB VERSUS BEVACIZUMAB MONOTHERAPY AS FIRST-LINE MAINTENANCE THERAPY IN HER2-EXPRESSING OVARIAN CANCER - DS8201-772 |
III |
in corso |
CANCRO OVARICO |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
PHASE 3 MULTICENTER, OPEN LABEL, RANDOMIZED STUDY OF RMC-6236 VERSUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC RAS[MUT] NSCLC - RMC-6236-301 |
III |
in corso |
CARCINOMA POLMONARE NSCLC |
- SC Oncologia Clinica Sperimentale Toraco - Polmonare |
